Mucopolysaccharidosis I Clinical Trial
OBJECTIVES: I. Evaluate bronchoalveolar lavage fluid and serum obtained from pediatric
patients with storage disorders prior to allogeneic hematopoietic stem cell transplantation
(HSCT) for the presence of proinflammatory cytokines and for the production of nitric oxide
by alveolar macrophages to identify possible risk factors for pulmonary complications.
II. Investigate the underlying mechanism for the development of significant pulmonary
complications in these patients during HSCT.
III. Evaluate bronchoalveolar lavage fluid and serum obtained from these same patients at
the time a pulmonary complication develops post-HSCT, or at 60 days post-HSCT if there has
been no pulmonary complications.
PROTOCOL OUTLINE:
Patients undergo bronchoscopy with bronchoalveolar lavage (BAL) prior to allogeneic
hematopoietic stem cell transplantation (HSCT). ELISA assays for cytokines are performed.
Patients are followed post-HSCT for the development of transplant related pulmonary
complications. A repeat bronchoscopy with BAL is performed at the time pulmonary
complications develop or at day 60 post-HSCT if no complications develop. Cytokine assays
are repeated.
;
Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01675674 -
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
|
N/A | |
Completed |
NCT00741338 -
Immune Tolerance Study With Aldurazyme® (Laronidase)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT04227600 -
A Study of JR-171 in Patients With Mucopolysaccharidosis I
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04453085 -
An Extension Study of JR-171-101 Study in Patients With MPS I
|
Phase 1/Phase 2 | |
Completed |
NCT05134571 -
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
|
Phase 4 | |
Terminated |
NCT00418821 -
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
|
Phase 4 | |
Completed |
NCT03071341 -
Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I
|
Phase 1/Phase 2 | |
Completed |
NCT03053089 -
Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I
|
Phase 1/Phase 2 | |
Completed |
NCT00146757 -
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old
|
Phase 2 | |
Active, not recruiting |
NCT04628871 -
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
|
||
Completed |
NCT02597114 -
Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
|
Phase 1 | |
Terminated |
NCT00748969 -
Clinical Trial of Growth Hormone in MPS I, II, and VI
|
Phase 2/Phase 3 | |
Terminated |
NCT00215527 -
Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I
|
Phase 1 | |
Recruiting |
NCT05619900 -
Registry of Patients Diagnosed With Lysosomal Storage Diseases
|
||
Completed |
NCT00146770 -
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
|
Phase 3 | |
Completed |
NCT00176917 -
Stem Cell Transplantation for Hurler
|
Phase 2 | |
Completed |
NCT00176891 -
Stem Cell Transplant w/Laronidase for Hurler
|
Phase 2 | |
Active, not recruiting |
NCT03153319 -
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
|
Phase 1/Phase 2 | |
Completed |
NCT00852358 -
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
|
N/A |